Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regen BioPharmaRGBP +55.00% EV-to-EBIT is -2.08 as of Jul. 15, 2026. The stock has 7 warning signs investors should review. Among 372 Biotechnology companies, Regen BioPharma ranks worse than 268816.94% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Regen BioPharma's Enterprise Value for the quarter that ended in Mar. 2026 was $1.22 Mil.
Regen BioPharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regen BioPharma EV-to-EBIT Related Terms
Regen BioPharma EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Regen BioPharma's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Regen BioPharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regen BioPharma EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regen BioPharma's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Regen BioPharma's EV-to-EBIT falls into.
Regen BioPharma's current Enterprise Value is $1.06 Mil.
Regen BioPharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regen BioPharma (RGBP) has a EV-to-EBIT of -2.08 as of Jul. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Regen BioPharma and its competitors. According to the industry distribution chart, Regen BioPharma ranks #999999 out of 372 companies in the Biotechnology industry.
Is Regen BioPharma's EV-to-EBIT too high?
Regen BioPharma's current EV-to-EBIT is -2.08. Based on the distribution chart, Regen BioPharma ranks #999999 out of 372 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Regen BioPharma's EV-to-EBIT compare to SIGY and ENDV?
According to the Biotechnology industry distribution chart, Regen BioPharma ranks #999999 out of 372 companies for EV-to-EBIT. This places Regen BioPharma in the lower half of its industry. The industry median EV-to-EBIT is 13.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.35, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Regen BioPharma and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regen BioPharma's current EV-to-EBIT is -2.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99.2% below its estimated fair value. The current EV-to-EBIT is -2.08. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current EV-to-EBIT is -2.08 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGBP has been successfully added to your 
